Hudson Bay Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Hudson Bay Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-42,370	Closed	-$27.8K	–	1630
2025 Q1	$27.8K	Buy	+42,370	New	+$44.9K	﹤0.01%	1213
2024 Q3	–	Sell	-135,000	Closed	-$48.4K	–	1015
2024 Q2	$48.4K	Sell	135,000 -1,238,500	-90%	-$669K	﹤0.01%	678
2024 Q1	$921K	Sell	1,373,500 -1,126,500	-45%	-$817K	0.01%	545
2023 Q4	$1.36M	Buy	2,500,000 +1,201,500	+93%	+$554K	0.01%	495
2023 Q3	$779K	Sell	1,298,500 -26,500	-2%	-$28.4K	0.01%	585
2023 Q2	$1.72M	Buy	1,325,000 +125,000	+10%	+$171K	0.01%	524
2023 Q1	$2.11M	Buy	1,200,000 +42,400	+4%	+$121K	0.02%	509
2022 Q4	$3.63M	Buy	1,157,600 +257,600	+29%	+$1,000K	0.04%	450
2022 Q3	$4.41M	Hold	900,000	–	–	0.04%	463
2022 Q2	$3.73M	Buy	900,000 +120,000	+15%	+$519K	0.03%	564
2022 Q1	$4.53M	Buy	780,000 +180,000	+30%	+$1.07M	0.06%	409
2021 Q4	$4.5M	Buy	600,000 +125,000	+26%	+$1.09M	0.05%	377
2021 Q3	$4.28M	Buy	475,000 +25,000	+6%	+$247K	0.06%	405
2021 Q2	$5.39M	Buy	450,000 +115,000	+34%	+$1.3M	0.07%	314
2021 Q1	$4.2M	Sell	335,000 -25,000	-7%	-$337K	0.05%	345
2020 Q4	$5.62M	Sell	360,000 -120,000	-25%	-$1.41M	0.06%	208
2020 Q3	$4.54M	Sell	480,000 -40,000	-8%	-$433K	0.07%	248
2020 Q2	$4.66M	Sell	520,000 -155,000	-23%	-$1.44M	0.08%	207
2020 Q1	$4.3M	Buy	675,000 +415,000	+160%	+$3.08M	0.11%	174
2019 Q4	$2.18M	Buy	260,000 +80,000	+44%	+$736K	0.05%	270
2019 Q3	$1.63M	Sell	180,000 -20,000	-10%	-$224K	0.05%	275
2019 Q2	$2.15M	Buy	200,000 +170,000	+567%	+$1.81M	0.05%	266
2019 Q1	$286K	Hold	30,000	–	–	﹤0.01%	636
2018 Q4	$344K	Buy	30,000 +10,000	+50%	+$124K	﹤0.01%	712
2018 Q3	$339K	Sell	20,000 -10,000	-33%	-$152K	﹤0.01%	644
2018 Q2	$426K	Buy	+30,000	New	+$498K	0.01%	709
2017 Q3	–	Sell	-45,000	Closed	-$396K	–	509
2017 Q2	$396K	Buy	+45,000	New	+$289K	0.01%	463

Other funds holding SGMO

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hudson Bay Capital Management's SGMO Position: Q2 2025 in Review

Hudson Bay Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2025, closing a stake of 42,370 shares — an estimated $27.8K sold.

Hudson Bay Capital Management first reported a position in SGMO in Q2 2017 and held it in 27 quarters. The position peaked at $5.62M in Q4 2020. 114 funds tracked by Wall St. Rank hold SGMO as of Q2 2025.

Hudson Bay Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
Hudson Bay Capital Management sold 42,370 SANGAMO THERAPEUTICS INC shares in Q2 2025, an estimated $27.8K.
Hudson Bay Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2017 and held it in 27 quarters.
Hudson Bay Capital Management's SANGAMO THERAPEUTICS INC position peaked at $5.62M in Q4 2020.
114 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2025.

Based on Hudson Bay Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.